Relationship of the CD22 Immunotoxin Dose and the Tumour Establishment in a SCID Mice Model

References

• Thrush G. R., Lark L. R., Clinchy B. C., Vitetta E. S. Immunotoxins: an update. Annual Review of Immunology. 1983; 14: 49–71
   Web of Science ®Google Scholar
• Preijers F. W. Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins. Leukemia and Lymphoma 1993; 9: 293–304
   PubMed Web of Science ®Google Scholar
• Stirpe F., Barbieri L. Ribosome-inactivating proteins up to date. Federatian of Biochemical Societies 1986; 195: 1–8
   PubMed Web of Science ®Google Scholar
• Kehrl J. H., Riva A., Wilson G. L., Thevenin C. Molecular mechanisms regulating CD19. CD20 and CD22 gene expression. Immunology Today. 1994; 15: 432–436
   PubMedGoogle Scholar
• Shen G. L., Li J. L., Ghetie M. A., Ghetie V., May R. D., Till M., Brown A. N., Relf M., Knowles P., Uhr J. W. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. International Journal of Cancer 1988; 42: 792–797
   PubMed Web of Science ®Google Scholar
• Kreitman R. J., Hansen H. J., Jones A. L., Fitzgerald D. J., Goldenberg D. M., Pastan I. Pseudomonas exo-toxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Research 1993; 53: 819–825
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Richardson J., Tucker T., Jones D., Uhr J. W., Vitetta E. S. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Research 1991; 51: 5876–5880
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., May R. D., Till M., Uhr J. W., Ghetie V., Knowles P. P., Relf M., Brown A., Wallace P. M., Janossy G. Evaluation of ricin A chain-containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Research 1988; 48: 2610–2617
   PubMed Web of Science ®Google Scholar
• Van Horssen P. J., Van Oosterhout Y. V., De Witte T., Preijers F. W. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules. Scandinavian Journal of Immunology. 1995; 41: 563–569
   PubMed Web of Science ®Google Scholar
• Van Horssen P. J., Preijers F. W., Van Oosterhout Y. V., De Witte T. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. International Journal of Cancer 1996; 68: 378–383
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Tucker K., Richardson J., Uhr J. W., Vitetta E. S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD 19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315–2320
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Tucker K., Richardson J., Uhr J. W., Vitetta E. S. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 1994; 84: 702–707
   PubMed Web of Science ®Google Scholar
• Mansfield E., Pastan I, Fitzgerald D. J. Chancterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjugate Chemistry 1996; 7: 557–563
   PubMed Web of Science ®Google Scholar
• Ghetic M. A., Podar E. M., Gordon B. E., Pantazis P., Uhr J. W., Vitetta E. S. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced. disseminated Daudi lymphoma. International Journal of Cancer 1996; 68: 93–96
   PubMed Web of Science ®Google Scholar
• Ghetie V., Engert A., Schnell R., Vitetta E. S. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. Cancer Letters 1995; 98: 97–101
   PubMed Web of Science ®Google Scholar
• Amlot P. L., Stone M. J., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetic V. A phase I study of an anti-CD22-deglyco-sylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993; 82: 2624–2633
   PubMed Web of Science ®Google Scholar
• Sausville E. A., Headlee D., Stetler Stevenson M., Jaffe E. S., Solomon D., Figg W. D., Herdt J., Kopp W. C., Rager H., Steinberg S. M. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 1905; 85: 3457–3465
   Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R, Cunningham U. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Research. 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• Senderowicz A. M., Vitetta E. S., Headlee D., Ghetie V., Uhr J. W., Figg W. D., Lush R. M., Stetler Stevenson M., Kershaw O., Kingma D. W., Jaffe E. S., Sausville E. A. Complete sustained response of a refractory. post-transplantation Large B-cell lymphoma to an anti-CD22 immunotoxin. Annals of Internal Medicine 1997; 126: 882–885
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Ghetie V, Vitetta E. S. Immunotoxins for the treatment of B-cell lymphomas. Molecular Medicine. 1997; 3: 420–427
   PubMed Web of Science ®Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Research 1988; 111: 6396–6403
   Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Knyba R. E., Wawrzynezak E. J., Blakey D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Research. 1987; 47: 5924–5931
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Vitetta E. S. Recent developments in immunotoxin therap. Current Opinions in Immunology 1994; 6: 707–714
   PubMed Web of Science ®Google Scholar
• Wu M. Enbancement of immunotoxin activity using chemical and biological reagents. British Journal of Cancer. 1997; 75: 1347–1355
   PubMed Web of Science ®Google Scholar
• Flavell D. J., Boehm D. A., Emery L., Noss A., Ramsay A., Flavell S. U. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CDIY- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. International Journal of Cancer 1995; 62: 337–344
   PubMed Web of Science ®Google Scholar
• Van Horssen P. J., Van Oosterhout Y. V., Backus H. H., Van Oijen Bongaerts M. G.R., De Witte T., Preijers F. W. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A. Leukemia 1990; 13: 241–249
   Web of Science ®Google Scholar
• Press O. W., De Santes K., Anderson S. K., Geissler F. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropie amines and carboxylic ionophores. Cancer Research 1990; 50: 1243–1250
   PubMed Web of Science ®Google Scholar
• Laurent G., Pris J., Farcet J. P., Carayon P., Blythman H., Casellas P., Poncelet P., Jansen F. K. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood. 1986; 67: 1680–1687
   PubMed Web of Science ®Google Scholar
• Dedrick R. L., Flessner M. F. Pharmacokinetic considerations on monoclonal antibodies. Progress in Clinical and Biological Research 1989; 288: 429–438
   PubMedGoogle Scholar
• Grossbard M. L., Nadler L. M. Immunotoxin therapy of lymphoid neoplasms. Seminars in Hematology 1994; 31: 88–97
   PubMed Web of Science ®Google Scholar
• Soler Rodriguez A. M., Ghetic M. A., Oppenheimer Marks N., Uhr J. W., Vitetta E. S. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Experimental Cell Research 1993; 206: 227–231
   PubMed Web of Science ®Google Scholar
• Casellas P., Bourrie B. J., Gros P., Jansen F. K. Kinetics of cytotoxicity induced by immunotoxins Enhancement by lysosomotropic amines and carboxylic ionophores. Journal of Biological Chemistry 1984; 259: 9359–9364
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S., Bjorn M. J., Houston L. L. Recombinant rich A chin conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Research 1989; 49: 613–417
   PubMed Web of Science ®Google Scholar
• Ghetie M. A., Richardson J., Tucker T., Jones D., Uhr J. W., Vitetta E. S. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. International Journal of Cancer. 1990; 45: 481–485
   PubMed Web of Science ®Google Scholar